Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 4, pp 579–585 | Cite as

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

  • A. R. Clamp
  • P. Schöffski
  • J. W. Valle
  • R. H. Wilson
  • S. Marreaud
  • A.-S. Govaerts
  • M. Debois
  • D. Lacombe
  • C. Twelves
  • J. Chick
  • G. C. Jayson
  • on behalf of the EORTC New Drug Development Group
Original Article



OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor. This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.


A 3+3 study design was utilized at predefined dose levels. Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity.


Fourteen patients received 76 cycles of treatment. At the highest dose level (OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose reductions. The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen. PK analysis showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin. Partial radiological responses were documented in two patients.


The recommended regimen for further investigation is OSI-7904L 9 mg/m2 and oxaliplatin 130 mg/m2.


Phase I OSI-7904L Oxaliplatin Thymidylate synthase Colorectal carcinoma 



The authors would like to thank Dr. D. W. Drolet for his assistance in the pharmacokinetic analyses.

Funding source

The study sponsor was OSI Pharmaceuticals Inc. Study design, data collection, interpretation and decision to submit the manuscript for publication were undertaken by the EORTC in conjunction with the authors.

Conflict of interest statement

J. Chick is an employee of OSI Pharmaceutical Inc. and hold share options in this company. None of the other authors have any conflict of interest.


  1. 1.
    Colorectal Cancer Collaborative Group (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321:531–535CrossRefGoogle Scholar
  2. 2.
    Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  3. 3.
    De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment for metastatic colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  4. 4.
    Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMedCrossRefGoogle Scholar
  5. 5.
    Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338PubMedCrossRefGoogle Scholar
  6. 6.
    De Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMedGoogle Scholar
  7. 7.
    Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 19:4097–4106PubMedGoogle Scholar
  8. 8.
    Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/ tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616PubMedCrossRefGoogle Scholar
  9. 9.
    Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW (2004) Pharmacokinetics, safety and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther 309:894–902PubMedCrossRefGoogle Scholar
  10. 10.
    Beutel G, Glen H, Schöffski P et al (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 11:5487–5495PubMedCrossRefGoogle Scholar
  11. 11.
    Winski S, Nilsson C, Brown E et al (2002) In vivo antitumor efficacy of liposomal OSI-7904L in human tumor xenografts. NCI-EORTC-AACR Molecular targets and cancer therapeutics meeting, 2002 Abstract 119Google Scholar
  12. 12.
    Pendyala L, Leichman CG, Clark K et al (2001) Oxaliplatin influences the intra-tumoral expression of γ-glutamylcysteine synthetase and thymidylate synthase genes in patients with esophagus cancer. Proc Am Soc Clin Oncol 20, 351aGoogle Scholar
  13. 13.
    Kawakami K, Omura K, Kanehira E et al (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249–3252PubMedGoogle Scholar
  14. 14.
    Chen J, Hunter DJ, Stampfer MJ et al (2003) Polymorphism in the thymidylate synthase promoter enhancer region modifies risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 12:958–962PubMedGoogle Scholar
  15. 15.
    Mandola MV, Stoehlmacher J, Muller-Weeks S et al (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898–2904PubMedGoogle Scholar
  16. 16.
    Morganti M, Ciantelli M, Giglioni B et al (2005) Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176–2183PubMedCrossRefGoogle Scholar
  17. 17.
    Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594–2601PubMedCrossRefGoogle Scholar
  18. 18.
    Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354–1357PubMedGoogle Scholar
  19. 19.
    Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354PubMedGoogle Scholar
  20. 20.
    Cancer Therapy Evaluation Programme (2003) Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. December 12 2003. (
  21. 21.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  22. 22.
    Falk SJ, Anthoney A, Eatock M et al (2006) Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 95:450–456PubMedCrossRefGoogle Scholar
  23. 23.
    Graham MA, Lockwood GF, Greenslade D et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–1218PubMedGoogle Scholar
  24. 24.
    Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303PubMedCrossRefGoogle Scholar
  25. 25.
    Maindrault-Goebel F, de Gramont A, Louvet C et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000–1005PubMedCrossRefGoogle Scholar
  26. 26.
    Ford HER, Mitchell F, Cunningham D et al (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8:103–109PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • A. R. Clamp
    • 1
  • P. Schöffski
    • 2
  • J. W. Valle
    • 1
  • R. H. Wilson
    • 3
  • S. Marreaud
    • 4
  • A.-S. Govaerts
    • 4
  • M. Debois
    • 4
  • D. Lacombe
    • 4
  • C. Twelves
    • 4
  • J. Chick
    • 5
  • G. C. Jayson
    • 1
  • on behalf of the EORTC New Drug Development Group
  1. 1.Cancer Research UK and University of Manchester Department of Medical OncologyChristie HospitalManchesterUK
  2. 2.Department of Hematology, Hemostaseology and OncologyHannover Medical SchoolHannoverGermany
  3. 3.Centre for Cancer Research and Cell BiologyQueen’s University BelfastBelfastUK
  4. 4.EORTC New Drug Development Program (NDDP)BrusselsBelgium
  5. 5.OSI Pharmaceuticals IncOxfordUK

Personalised recommendations